

<!--StartFragment-->RESULT 4

ABB78741

ID ABB78741 standard; protein; 89 AA.

XX

AC ABB78741;

XX

DT 22-JUL-2002 (first entry)

XX

DE Human calsyntenin-1 cleaved protein sequence SEQ ID NO:30.

XX

KW Human; calsyntenin-1; calsyntenin-2; calsyntenin-3; nervous system;

KW calcium binding protein; neuroprotective; antiinflammatory; nootropic;

KW anticonvulsant; cerebroprotective; cytostatic; ophthalmological; tumour;

KW analgesic; neuroleptic; vaccine; gene therapy; nervous system disorder;

KW metastasis; ARP2/3 complex; neoangiogenesis; neurodegenerative disease;

KW neuroinflammatory disease; epileptic seizure; retinal disease;

KW pathological pain syndrome; psychiatric disorder.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN WO200222819-A2.

XX

PD 21-MAR-2002.

XX

PF 13-SEP-2001; 2001WO-IB001662.

XX

PR 14-SEP-2000; 2000EP-00810830.

XX

PA (UYZU-) UNIV ZUERICH.

XX

PI Sonderegger P, Hintsch G, Kinter J, Meskenaite V, Schrimpf S;

PI Vogt L, Zurlinden A;

XX

DR WPI; 2002-404811/43.

XX

PT Isolated nervous system calcium binding protein, selected from

PT calsyntenin-1-3, useful as valuable agents for the treatment of disorders

PT of nervous system and in the development of drugs.

XX

PS Example 14; Page 76; 158pp; English.

XX

CC The present invention describes an isolated nervous system calcium
 CC binding protein (I), selected from calsyntenin-1, calsyntenin-2 or
 CC calsyntenin-3, used as a pharmaceutical, having calcium binding activity
 CC and/or capable of binding Arp2/3 complex. (I) has neuroprotective,
 CC antiinflammatory, nootropic, anticonvulsant, cerebroprotective,
 CC cytostatic, ophthalmological, analgesic and neuroleptic activities. (I)
 CC and the polynucleotide encoding it (II) can be used in vaccines and in
 CC gene therapy. (I) and (II) are useful for the screening and for the
 CC preparation of a medicament for the treatment of disorders, in particular
 CC disorders of nervous system, particularly central nervous system
 CC including brain. (I) and (II) are also useful for the preparation of a
 CC medicament for the treatment of tumours including prevention or reduction
 CC of growth, expansion infiltration and metastasis of primary and
 CC metastatic tumours, in particular brain tumour or tumours of retina,
 CC where the tumours involve an enhanced activity of ARP2/3 complex or
 CC protease functionally connected with (I), in their growth, expansion,
 CC infiltration, metastasis and promotion of blood vessels or
 CC neoangiogenesis. (I) and (II) are also useful for treating, preventing or
 CC ameliorating negative effects of neurodegenerative diseases or
 CC neuroinflammatory diseases or epileptic seizures, and for treating,
 CC ameliorating or preventing retinal diseases, pathological pain syndromes,
 CC psychiatric disorders, learning and memory functions in healthy persons,
 CC and for treating tumours. The present sequence represents a human
 CC calsyntenin-1 cleaved protein sequence, which is used in an example from
 CC the present invention

XX

SQ Sequence 89 AA;

Query Match 100.0%; Score 104; DB 5; Length 89;

Best Local Similarity 100.0%; Pred. No. 9.4e-09;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 QFVHPEHRSFVDLSGHNLA 19

|||||||

Db 57 QFVHPEHRSEFVDLSGHNLA 75

<!--EndFragment-->